Viruses that can invade host cells, initiate cancer and then flee from their own trail of destruction could be stopped in their tracks, say researchers writing in the September issue of the Journal of General Virology.
Scientists at the University of Cambridge have not only provided the first unequivocal evidence for the 'hit-and-run hypothesis' - explaining how some viruses might cause cancer and then mysteriously disappear - but have...
Insufficiency linked to inferior event-free and overall survival in non-Hodgkin's subtypes
Publish date: Aug 17, 2010
TUESDAY, Aug. 17 (HealthDay News) -- In patients with two non-Hodgkin's lymphoma subtypes, vitamin D insufficiency is associated with inferior overall survival (OS) as well as inferior event-free survival (EFS), according to a study published online Aug. 16 in the Journal of Clinical Oncology.
In a prospective cohort of 983 newly diagnosed patients...
We cannot escape the realities of biology. Just as children rescued from leukemia and lymphoma live to grow into adults who must confront the adverse effects of their curative treatment, people rescued from AIDS by HAART (highly active antiretroviral therapy) are showing a substantially increased risk of cancers other than the "AIDS-defining" malignancies designated by the Centers for Disease Control in the 1980s: Kaposi sarcoma, non-Hodgkin lymphoma (NHL),...
Stand Up to Cancer 'Teams' Up with CBS' Survivor for Online Fundraising Program to 'Challenge The Odds'
Top fundraising teams will be highlighted during Sept. 10th nationally televised broadcast
NEW YORK, Aug. 17 /PRNewswire-USNewswire/ -- As part of a new long-term alliance, Stand Up To Cancer (SU2C) is gearing up for its next Team Fundraising Challenge by joining forces with one of television's most popular shows, Survivor on CBS. For the first time ever, Survivor will...
Seattle-based Cell Therapeutics (CTI) has taken another step towards gaining European approval for its new treatment for non-Hodgkin's lymphoma.
CTI said one of the last pieces in the puzzle which will allow them to begin marketing pixantrone has been validated by the European Medicines Agency (EMEA), and takes them one step further to marketing the drug across the continent later this year.
